You are here
Influenza activity during the 2017–2018 season was high, with an estimated 48.8 million people becoming ill, 959,000 hospitalizations and 79,400 deaths. Xofulza (baloxavir marboxil) is a new antiviral agent approved by the FDA on October 24, 2018. This drug forecast article reviews the pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, safety profile, and place in therapy of Xofluza.
Steglatro (ertugliflozin) for glycemic control in adults with type-2 diabetes mellitus
Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections
Naldemedine (Symproic) for opioid-induced constipation
Etelcalcetide (Parsabiv) for hyperparathyroidism in adults with chronic kidney disease on hemodialysis